



March 5, 2026

FOR IMMEDIATE RELEASE

Company name : Avex Inc.
Representative : Katsumi Kuroiwa, Representative Director, CEO
(Securities code: 7860, TSE Prime Market)
Contact : Shinji Hayashi, Representative Director, CFO
TEL: 0570(020)050

Notice Regarding an Absorption-Type Merger of a Wholly-Owned Subsidiary (Short-form Merger)

Avex Inc. (“the Company”) hereby announces that its Board of Directors resolved at a meeting held on February 26, 2026, to conduct an absorption-type merger (“the Merger”) of its wholly-owned subsidiary, Avex Healthcare Empower LLC (“AHE”), with an effective date of April 1, 2026.

Please note that because the Merger is a simplified absorption-type merger targeting a wholly-owned subsidiary, some disclosure items and details have been omitted.

We apologize for the delay in disclosing the notice of this merger, which should have been disclosed in a timely manner.

Details

1. Purpose of the Merger

The purpose of the Merger is to consolidate management resources and strive for efficient organizational operations within the Company group.

2. Summary of the Merger

(1) Schedule of the Merger

Date of Board of Directors’ resolution: February 26, 2026

Date of execution of the merger agreement: February 26, 2026

Scheduled date of the merger (effective date): April 1, 2026 (planned)

(Note) The Merger is a short-form merger for the Company as prescribed in Article 796, Paragraph 2 of the Companies Act; therefore, the Company will not hold a general meeting of shareholders to approve the merger agreement. Regarding AHE, consent from all members was obtained as of February 26, 2026, pursuant to Article 793, Paragraph 1 of the Companies Act.

(2) Method of the Merger

The Merger is an absorption-type merger in which the Company will be the surviving company and AHE will be the dissolving company, and AHE will be dissolved.

(3) Details of Allotment Related to the Merger

Because AHE is a wholly-owned subsidiary of the Company, there will be no issuance of new shares or allotment of money, etc., resulting from the Merger.

(4) Treatment of Stock Acquisition Rights and Bonds with Stock Acquisition Rights of the Dissolving Company

AHE has not issued any stock acquisition rights or bonds with stock acquisition rights.

3. Overview of the Merging Companies

	Surviving Company	Dissolving Company
(1) Name	Avex Inc.	Avex Healthcare Empower LLC
(2) Location	1-4-1 Mita, Minato-ku, Tokyo	1-4-1 Mita, Minato-ku, Tokyo
(3) Title and Name of Representative	Katsumi Kuroiwa, Representative Director, CEO	Yasuhito Hoyamatsu, Representative Employee of Avex Inc., Authorized Representative
(4) Business Description	Holding company overseeing the Group	Advertising agency/promotion business, event planning and production business, etc.
(5) Capital	4,836 million yen	30 million yen
(6) Date of Establishment	April 11, 1988	January 22, 2018
(7) Number of Shares Issued	45,919,30 shares	-
(8) End of Fiscal Year	March 31st	March 31st
(9) Major Shareholders and Shareholding Ratios	CyberAgent, Inc. 12.98%, The Master Trust Bank of Japan, Ltd. (Trust Account) 10.90%	Avex Inc. 100%
(10) Operating Results and Financial Position for the Preceding Fiscal Year		
Fiscal Year	Fiscal year ended March 2025	Fiscal year ended March 2025 (Non-consolidated)
Total Assets	105,960 million yen	27 million yen
Net Assets	51,112 million yen	-106 million yen
Net Assets per Share	1,182.34円	-
Net Sales	131,691 million yen	22 million yen
Operating Profit	-1,819 million yen	- 41 million yen
Ordinary Profit	-1,703 million yen	- 41 million yen
Profit Attributable to Owners of Parent	1,138 million yen	- 29 million yen
Net Profit per Share	26.11 yen	-

4. Status of the Company After the Merger

There will be no changes to the Company's name, location, title and name of the representative, business description, capital, or fiscal year-end as a result of the Merger.

5. Future Outlook

Because the Merger is a merger between the Company and its wholly-owned subsidiary, the impact on consolidated financial results is minor.

End